Rheumatic Diseases and Biosimilars: Evidence about Switch from Originators to Biosimilars in the Real Life
Biosimilars are broadly available for the treatment of several diseases including inflammatory arthritis. Thanks to biosimilars it has been possible to treat a greater number of rheumatic patients who previously were undertreated due to the high cost of originators, in several countries. There are a...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2021
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/78727 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Rheumatic Diseases and Biosimilars: Evidence about Switch from Originators to Biosimilars in the Real Life
- Medicamentos biosimilares : régimen jurídico y garantías sanitarias
- Immunogenicity Study of Biosimilar Candidates
- Biosimilar Monoclonal Antibodies in Latin America
- Gestión clínica, incentivos y biosimilares /
- Biosimilars in Inflammatory Bowel Diseases: General Concepts and Clinical Implications
- Introductory Chapter: Biosimilars - A Regulatory and Clinical Perspective